A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)

Part of paid clinical trials in Paducah, Kentucky.

Sponsor
Genentech, Inc.
Study ID
NCT02698566
Phase
PHASE3
Status
Completed

Conditions

  • Macular Edema

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ranibizumab — DRUG
    Patients will receive single ITV injection of ranibizumab 0.5 mg delivered via PFS on Day 1.

Study Details

This is a multicenter study designed to evaluate usability of ranibizumab PFS in patients with neovascular age related macular degeneration or macular edema secondary to retinal vein occlusion.

Key Dates

First listed
Mar 3, 2016
Start date
Mar 21, 2016
Status verified
Aug 2017
Primary completion
Apr 5, 2016
Completion
Apr 5, 2016

Study Design

Enrollment
35 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: Ranibizumab PFS
    Healthcare professionals (HCPs) will administer ITV injections of ranibizumab 0.5 mg delivered via PFS to enrolled patients (1 injection to each patient) on Day 1.

Primary Outcome Measure

Percentage of Successful Task Completions [ Time Frame: Day 1 ]

Locations (4)

FacilityCityStateZIPSite coordinators
Paducah Retinal CenterPaducahKentucky42001-
Char Eye Ear &Throat AssocCharlotteNorth Carolina28210-
Southeastern Retina AssociatesChattanoogaTennessee37421-
Charles Retina InstitutionGermantownTennessee38138-

Find similar trials in Paducah, KY

By research site
Paducah Retinal Center· Paducah, KYChar Eye Ear &Throat Assoc· Charlotte, NCSoutheastern Retina Associates· Chattanooga, TNCharles Retina Institution· Germantown, TN

Related Studies